Brain markers may reveal who responds best to suicide treatments

NCT ID NCT07723066

Not yet recruiting Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study looks for brain and behavioral markers that could predict how people with suicidal thoughts respond to ketamine or electroconvulsive therapy (ECT). Researchers will use brain scans, EEG, and clinical assessments before and after treatment in 60 adults with major depression and suicidal thoughts. The goal is to identify circuit-level biomarkers linked to treatment response, which could eventually guide more personalized care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors match suicidal patients to the most effective treatment faster, potentially saving lives.
What could go wrong: This is an observational study, not a treatment trial, so it will not directly test any new therapy. The findings may not apply to all patients or lead to immediate clinical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Behavior bipolar disorder major depressive disorder Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE EPISODE (MDE) SUICIDAL THOUGHTS AND BEHAVIORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.